Rituximab drug more effective than fingolimod for patients with highly active multiple sclerosis

Rituximab drug more effective than fingolimod for patients with highly active multiple sclerosis: A new study indicates that rituximab is more effective than fingolimod for preventing relapses in patients with highly active multiple sclerosis switching from treatment with natalizumab.

Rituximab shows second-line promise in autoimmune limbic encephalitis

Rituximab shows second-line promise in autoimmune limbic encephalitis: Rituximab is an effective and well-tolerated second-line treatment for patients with autoimmune limbic encephalitis, suggests research.

Study examines use of cryoablation to reduce phantom limb pain

Study examines use of cryoablation to reduce phantom limb pain: J. David Prologo, MD, delivered new findings from an Emory Interventional Radiology and Image Guided Medicine study at the Society of Interventional Radiology's 2016 Annual Scientific Meeting. The study examines the use of cryoablation, or extreme cold, to reduce phantom limb pain (PLP) - a condition that causes individuals to perceive chronic pain in amputated limbs. Emory's study shows interventional radiologists who applied cold blasts to patients suffering from PLP significantly reduced their level of pain.

Patients with genotype 1 chronic HCV infection achieve high SVR rates with VIEKIRAX EXVIERA

Patients with genotype 1 chronic HCV infection achieve high SVR rates with VIEKIRAX EXVIERA: AbbVie, a global biopharmaceutical company, today announced data showing that patients with genotype 1 (GT1) chronic hepatitis C virus (HCV) infection who received the recommended regimen of VIEKIRAX (ombitasvir/paritaprevir/ritonavir tablets) + EXVIERA (dasabuvir tablets), with or without ribavirin (RBV), achieved high sustained virologic response rates at 48 weeks post-treatment (SVR48), regardless of the presence of baseline resistance-associated variants (RAVs).

New clinical data highlights potential of AB-PA01 to treat P. aeruginosa infections in CF patients

New clinical data highlights potential of AB-PA01 to treat P. aeruginosa infections in CF patients: AmpliPhi Biosciences Corporation, a global leader in the development of bacteriophage-based antibacterial therapies to treat drug-resistant infections, presented data at the European Congress of Clinical Microbiology and Infectious Diseases summarizing both the in vitro and in vivo activity of its proprietary, investigational phage mix AB-PA01.

Novel nanoparticle drug delivery system for enhanced tumor penetration of cancer drugs

Novel nanoparticle drug delivery system for enhanced tumor penetration of cancer drugs: For more than a decade, biomedical researchers have been looking for better ways to deliver cancer-killing medication directly to tumors in the body. Tiny capsules, called nanoparticles, are now being used to transport chemotherapy medicine through the bloodstream, to the doorstep of cancerous tumors.

Study elucidates potential benefits of antiarrhythmic drugs for out-of-hospital cardiac arrest patients

Study elucidates potential benefits of antiarrhythmic drugs for out-of-hospital cardiac arrest patients: Paramedics often give heart rhythm stabilizing drugs to patients who are suffering out-of-hospital cardiac arrest when they fail to regain a stable heart rhythm after electrical shock treatment.

Innovative nano-therapy treatment can fight chronic inflammatory disorders, cancer

Innovative nano-therapy treatment can fight chronic inflammatory disorders, cancer

FDA Approves Defitelio (defibrotide sodium) for Hepatic Veno-Occlusive Disease Following Hematopoietic Stem-Cell Transplantation

FDA Approves Defitelio (defibrotide sodium) for Hepatic Veno-Occlusive Disease Following Hematopoietic Stem-Cell Transplantation